Kyverna Therapeutics
Harnessing the power of cell therapy in autoimmune disease.
160 employees · est. 2018 · Emeryville, United States
Zenas BioPharma
Enabling patients with autoimmune diseases to reimagine life
196 employees · est. 2020 · Waltham, United States
Kyverna Therapeutics is the older company (2018 vs 2020).
3 signals in the last 90 days
Side-by-Side Comparison
| Metric | Kyverna Therapeutics | Zenas BioPharma |
|---|---|---|
| Founded | ||
| Founded | 2018 older | 2020 |
| Headquarters | ||
| Headquarters | Emeryville, United States | Waltham, United States |
| Employees | ||
| Employees | 160 | 196 |
| Industry | ||
| Industry | Not tracked yet | Biopharma, Health Care, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | IPO | Series C |
| Total Funding | ||
| Total Funding | $489.00M | $318.00M |
| Funding Rounds | ||
| Funding Rounds | 6 | 3 |
| Services | ||
| Services | Development of CAR T-cell therapies for autoimmune diseases, Clinical trials management, Patient-centric therapeutic solutions, Next-generation cell therapy pipeline | Development of therapies for autoimmune diseases, Clinical trial management, Drug research and development, Commercialization of new therapies |
| Target Customers | ||
| Target Customers | Patients with autoimmune diseases, Healthcare providers specializing in rheumatology and neurology, Clinical research organizations | Patients with autoimmune diseases, Healthcare providers, Caregivers, Pharmaceutical investors |
| Taxonomy | ||
| Taxonomy | Cell Therapy, Biopharmaceuticals, Autoimmune Diseases, CAR T-cell Therapy, CD19-targeting, Neuroimmunology, Stiff Person Syndrome, Generalized Myasthenia Gravis, Multiple Sclerosis, Rheumatoid Arthritis, T-cell Engineering, Synthetic Biology, Curative Treatments, B-cell-driven Diseases, Autologous Therapies | Biopharmaceuticals, Autoimmune Diseases, Clinical-stage, Transformative Therapies, Monoclonal Antibody, BTK Inhibitor, CNS-penetrant, Small Molecule, Subcutaneous Injection, B Cell Lineage, Immunology, Macrophage Modulation, Microglial Cells, IL-17 Inhibitor, TYK2 Inhibitor |
| Website | ||
| Website | kyvernatx.com | zenasbio.com |
About Kyverna Therapeutics
Kyverna Therapeutics, founded in 2018, is a United States-based clinical-stage biopharmaceutical company that aims to revolutionize treatment for autoimmune diseases by leveraging cell therapy. Their slogan, "Harnessing the power of cell therapy in autoimmune disease," highlights their focus on prov...
About Zenas BioPharma
Zenas BioPharma, founded in 2020, is a clinical-stage global biopharmaceutical company headquartered in the United States. The company is devoted to transforming the lives of patients with autoimmune diseases, as encapsulated by its slogan: "Enabling patients with autoimmune diseases to reimagine li...
We will tell you when either one moves
BounceWatch watches Kyverna Therapeutics and Zenas BioPharma for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Kyverna Therapeutics and Zenas BioPharma — by email.
Frequently Asked Questions
Compare Kyverna Therapeutics with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Kyverna Therapeutics on 9 Jun 2026, and Zenas BioPharma on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.